Roche Acquiring Cervical Cancer Test Developer MTM Laboratories for up to $269M

Paired with Roche's HPV testing offerings, the deal will expand its cervical cancer testing capabilities.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.